Fluorinated cyclic amides as dipeptidyl peptidase IV inhibitors

a technology of dipeptidyl peptidase and fluorinated cyclic amide, which is applied in the field of compound, can solve the problems of limiting their use, adding significantly to the overall morbidity and mortality attributable to those diseases, and few pharmacological agents available to reduce adiposity effectively and acceptably, and achieves increased in vivo half-life, increased metabolic stability, and easy preparation and detection.

Inactive Publication Date: 2004-07-08
PFIZER INC
View PDF6 Cites 36 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0070] This invention also includes isotopically-labeled compounds, which are identical to those described by Formula I, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen and fluorine, such as .sup.2H, .sup.3H, .sup.13C, .sup.14C, .sup.15N, .sup.18O, .sup.17O, and .sup.18F, respectively. Compounds of the present invention, prodrugs thereof, and pharmaceutically acceptable salts of the compounds or of the prodrugs which contain the aforementioned isotopes and / or other isotopes of other atoms are within the scope of this invention. Certain isotopically-labeled compounds of the present invention, for example those into which radioactive isotopes such as .sup.3H and .sup.14C are incorporated, are useful in drug and / or substrate tissue distribution assays. Tritiated (i.e., .sup.3H), and carbon-14 (i.e., .sup.14C), isotopes are particularly preferred for their ease of preparation and detectability. Further, substitution with heavier isotopes such as deuterium (i.e., .sup.2H), can afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life or reduced dosage requirements and, hence, may be preferred in some circumstances. Isotopically labeled compounds of Formula I of this invention and prodrugs thereof can generally be prepared by carrying out the procedures disclosed in the schemes and / or in the Examples below, by substituting a readily available isotopically labeled reagent for a non-isotopically labeled reagent.

Problems solved by technology

The administration of an excess dose of insulin causes hypoglycemia, with consequences ranging from mild abnormalities in blood glucose to coma, or even death.
However, the clinically available hypoglycemics can have side effects which limit their use.
In addition, diabetes mellitus is a comorbid disease that frequently confounds hyperlipidemia, atherosclerosis and hypertension, adding significantly to the overall morbidity and mortality attributable to those diseases.
Currently few pharmacological agents are available that reduce adiposity effectively and acceptably.
Osteoporosis and the consequences of compromised bone strength are a significant cause of frailty, and of increased morbidity and mortality.
Heart disease is a major health problem throughout the world.
Myocardial infarctions are a significant source of mortality among those individuals with heart disease.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Fluorinated cyclic amides as dipeptidyl peptidase IV inhibitors
  • Fluorinated cyclic amides as dipeptidyl peptidase IV inhibitors
  • Fluorinated cyclic amides as dipeptidyl peptidase IV inhibitors

Examples

Experimental program
Comparison scheme
Effect test

example 1

(2S, 3S)-2-amino-3-methyl-1-(3,3,4,4-tetrafluoro-pyrrolidin-1-yl)-pentan-1--one

[0121] Step 1: [(1S, 2S)-2-Methyl-1-(3,3,4,4-tetrafluoro-pyrrolidine-1-car-bonyl)-butyl]-carbamic Acid Tert-Butyl Ester.

[0122] To a mixture of (L)-Boc-isoleucine (322 mg, 1.30 mmol), 3,3,4,4-tetrafluoro-pyrrolidine hydrochloride (300 mg, 1.67 mmol), hydroxybenzotriazole (225 mg, 1.67 mmol) and triethylamine (0.23 mL, 1.67 mmol) in dichloromethane (10 mL) was added 1-(-3-dimethylaminopropyl)-3-e-thylcarbodiimide hydrochloride (319 mg, 1.67 mmol). The mixture was stirred at room temperature overnight, diluted with ethyl acetate, washed with 2 N HCl, saturated sodium bicarbonate solution, water and brine, dried over magnesium sulfate and concentrated. The product was purified by flash-chromatography (hex / ethyl acetate, 4:1) and isolated as a white solid (415 mg, 86%).

[0123] The 3,3,4,4-tetrafluoro-pyrrolidine hydrochloride utilized in Step 1 may be prepared according to Chaudhry et al. J.Chem.Soc.; 1964; 874...

example 2

(2S, 3S)-2-amino-1-(3-fluoro-azetidin-1-yl)-3-methyl-pentan-1-one.

[0126] Step 1: [(1S,2S)-1-(3-Hydroxy-azetidine-1-carbonyl)-2-methyl-butyl]--carbamic Acid Tert-Butyl Ester.

[0127] [(1S,2S)-1-(3-Hydroxy-azetidine-1-carbonyl)-2-methyl-butyl]-carbami-c acid tert-butyl ester was prepared as analogously described in Step 1 of Example 1 from a mixture of (L)-Boc-isoleucine and 3-hydroxyazetidine. 3-Hydroxyazetidine was prepared according to Lee, J. et al. (Bioorg.Med.Chem.Lett. 2000, 10, 1063).

[0128] Step 2: [(1S, 2S)-1-(3-Fluoro-azetidine-1-carbonyl)-2-methyl-butyl]--carbamic Acid Tert-Butyl Ester.

[0129] To a cooled (-78.degree. C.) solution of diethylaminosulfur trifluoride (0.46 mL, 3.5 mmol) in dichloromethane (6 mL), was added dropwise a solution of [(1S, 2S)-1-(3-hydroxy-azetidine-1-carbonyl)-2-met-hyl-butyl]-carbamic acid tert-butyl ester (1.0 g, 3.5 mmol) in dichloromethane (4 mL). The mixture was warmed to room temperature, stirred overnight, then diluted with ethyl acetate and p...

example 3

(S)-2-amino-2-cyclohexyl-1-(3,3,4,4-tetrafluoro-pyrrolidin-1-yl)-ethanone

[0132] Step 1: (S)-[1-Cyclohexyl-2-oxo-2-(3,3,4,4-tetrafluoro-pyrrolidin-1--yl)-ethyl]-carbamic Acid Tert-Butyl Ester.

[0133] (S)-[1-Cyclohexyl-2-oxo-2-(3,3,4,4-tetrafluoro-pyrrolidin-1-yl)-eth-yl]-carbamic acid tert-butyl ester was prepared from (L)-Boc-cyclohexylglycine and 3,3,4,4-tetrafluoropyrrolidine as analogously described in Step 1 of Example 1.

[0134] Step 2: (S)-2-amino-2-cyclohexyl-1-(3,3,4,4-tetrafluoro-pyrrolidin--1-yl)-ethanone.

[0135] (S)-2-amino-2-cyclohexyl-1-(3,3,4,4-tetrafluoro-pyrrolidin-1-yl)-et-hanone was obtained by HCl treatment of (S)-[1-cyclohexyl-2-oxo-2-(3,3,4,4--tetrafluoro-pyrrolidin-1-yl)-ethyl]-carbamic acid tert-butyl ester as analogously described in Step 2 of Example 1. (mp 278.degree. C.).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
pHaaaaaaaaaa
temperatureaaaaaaaaaa
α-glucosidaseaaaaaaaaaa
Login to view more

Abstract

The invention relates to new therapeutically active and selective inhibitors of the enzyme dipeptidyl peptidase-IV, pharmaceutical compositions comprising the compounds and the use of such compounds for treating diseases that are associated with proteins that are subject to processing by DPP-IV, such as Type 2 diabetes mellitus, hyperglycemia, impaired glucose tolerance, metabolic syndrome (Syndrome X or insulin resistance syndrome), glucosuria, metabolic acidosis, cataracts, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, Type 1 diabetes, obesity, conditions exacerbated by obesity, hypertension, hyperlipidemia, atherosclerosis, osteoporosis, osteopenia, frailty, bone loss, bone fracture, acute coronary syndrome, infertility due to polycystic ovary syndrome, short bowel syndrome, anxiety, depression, insomnia, chronic fatigue, epilepsy, eating disorders, chronic pain, alcohol addiction, diseases associated with intestinal motility, ulcers, irritable bowel syndrome, inflammatory bowel syndrome and to prevent disease progression in Type 2 diabetes. The invention also relates to a method of identifying an insulin secretagogue agent for diabetes.

Description

[0001] This application is filed claiming priority from co-pending U.S. Provisional Application No. 60 / 86157, filed Jun. 4, 2002.[0002] The present invention relates to new therapeutically active and selective inhibitors of the enzyme dipeptidyl peptidase-IV (hereinafter "DPP-IV"), pharmaceutical compositions comprising the compounds and the use of such compounds for treating diseases that are associated with proteins that are subject to processing by DPP-IV, such as Type 2 diabetes, metabolic syndrome (Syndrome X or insulin resistance syndrome), hyperglycemia, impaired glucose tolerance, glucosuria, metabolic acidosis, cataracts, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, Type 1 diabetes, obesity, hypertension, hyperlipidemia, atherosclerosis, osteoporosis, osteopenia, frailty, bone loss, bone fracture, acute coronary syndrome, infertility due to polycystic ovary syndrome, short bowel syndrome, anxiety, depression, insomnia, chronic fa...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): C07D205/04C07D207/08C07D211/38
CPCC07D205/04C07D211/38C07D207/08
Inventor HULIN, BERNARDPARKER, JANICE C.
Owner PFIZER INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap